[CAS NO. 12777-70-7] Dryocrassin ABBA
PRODUCTS SPECIFICATIONS [12777-70-7]
DESCRIPTION [12777-70-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 820.83 |
| Molecular Formula | C43H48O16 |
| SMILES | OC1=C(C(O)=C(C(CCC)=O)C(O)=C1CC(C(C(C(C)=O)=C(O)C2(C)C)=O)=C2O)CC(C(O)=C(C(CCC)=O)C(O)=C3CC(C(C(C(C)=O)=C(O)C4(C)C)=O)=C4O)=C3O |
Summary
Dryocrassin ABBA (Dryocrassin) is an orally active flavonoid natural product derived from Dryopteris crassirhizoma , with antiviral and antibacterial activities [1] [2] . Dryocrassin ABBA exhibits antiviral activity against H5N1 avian influenza virus [1] . Dryocrassin ABBA inhibits the coagulase activity of Staphylococcus aureus vWbp [3] . Dryocrassin ABBA suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival [4] .
IC50 & Target
H5N1 avian influenza virus [1]
In Vitro
Dryocrassin ABBA (Dryocrassin) inhibits the activity of S. aureus SrtA (sortase A) with an IC 50 of 24.17 μM [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Dryocrassin ABBA (Dryocrassin) (0-33 mg/kg; i.g.; daily, 7 days from day 2 to day 8) exerts a significant dose-dependent antiviral effect in mice
[1]
.
Dryocrassin ABBA (100 mg/kg; s.c.; every 12 h for 96 h) can reduce infection and prevent mice from contracting
S. aureus
pneumonia
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | SPF BALB/C female mice inoculated intra-nasally with 10 4.5 ELD 50 H5N1 viruses in 100 μl saline [1] |
| Dosage: | 33, 18, and 12.5 mg/kg |
| Administration: | Oral gavage, daily, 7 days from day 2 to day 8 |
| Result: | Significantly reduced mortality, prolonged survival rate, and improved survival time throughout the infection period. Increased body weight and reduced lung lesions and virus loads. Significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α. |
| Animal Model: | Eight-week-old C57BL/6J mice infected with 30 μL of S. aureus Newman (2 × 10 8 CFU/10 μL) by intranasal administration [3] |
| Dosage: | 100 mg/kg |
| Administration: | Subcutaneous injection, every 12 h for 96 h |
| Result: | Resulted a significant increase in survival. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 16.67 mg/mL ( 20.31 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2183 mL | 6.0914 mL | 12.1828 mL |
| 5 mM | 0.2437 mL | 1.2183 mL | 2.4366 mL |
| 10 mM | 0.1218 mL | 0.6091 mL | 1.2183 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.67 mg/mL (2.03 mM); Clear solution
References
- [1] Ou C, et al. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. Front Microbiol. 2015 Jun 16;6:592.
- [2] Zhang B, et al. Molecular Mechanism of the Flavonoid Natural Product Dryocrassin ABBA against Staphylococcus aureus Sortase A. Molecules. 2016 Oct 26;21(11).
- [3] Li B, et al. An Inhibitory Effect of Dryocrassin ABBA on Staphylococcus aureus vWbp That Protects Mice From Pneumonia. Front Microbiol. 2019 Jan 23;10:7.
- [4] Fu RH, et al. Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival. Cell Transplant. 2014;23(4-5):641-56.
